Alnylam Pharmaceuticals shares jump around 5.5% as strong Q3 product revenue drives commercial momentum

Traders Union
All News
Stocks
Alnylam pharmaceuticals rises 5.40% today

Highlights

Shares of Alnylam Pharmaceuticals fell 25% in a single day after earnings revealed slower patient adoption and reimbursement obstacles.
Third-quarter product revenue reached $1.29 billion, up 52% year over year, with AMVUTTRA making up 87.5% of sales.
Alnylam Pharmaceuticals stock trades below key trend averages with a predicted price range of $158.97 to $174.51 over the next five days and a high probability of a downward move.

Share collapse as revenue gains offset by adoption and guidance concerns

Alnylam Pharmaceuticals recently reported a 25% single-day share-price drop following its October 29, 2026 earnings release, which included slower-than-expected patient adoption, reimbursement hurdles, and guidance for full-year TTR revenue near the lower end of its range. In the third quarter of 2026, product revenue reached $1.29 billion, a 52% year-over-year increase, with AMVUTTRA (vutrisiran) accounting for about 87.5% of sales. The company continues to focus on developing RNA interference therapeutics and maintains multiple commercial product streams.

Anton Kharitonov, expert at Traders Union, notes that despite a 5.4% rebound, ALNY remains below key moving averages. He observes ongoing bearish pressure, with technical indicators and sustained resistance dampening sentiment. Kharitonov highlights that volatility stays elevated while momentum signals remain weak. Although third-quarter revenue growth is impressive, concerns over slower adoption and lower-end guidance persist. "Rallies are likely to fade unless price reclaims $167.99 with strong volume — caution is warranted for now."

Viktoras Karapetjanc, expert at Traders Union, sees strong 52% year-over-year revenue growth as a sign of expanding fundamentals. He focuses on the momentum from AMVUTTRA and the ongoing development of RNA interference therapeutics. Karapetjanc believes that commercial focus positions Alnylam for long-term success despite near-term hurdles. He expects the underlying bullish structure to reassert with further product adoption and reimbursement progress. "Investors should watch for upward momentum above $167.99 — further growth is achievable as market confidence rebuilds."

Parshwa Turakhiya, analyst, views the recent 5.4% surge as a short-term sentiment play rather than a trend reversal. He notes the technical setup signals sideways action, with volatility high and resistance near $167.99. Turakhiya points out oversold readings could spark brief rebounds, but sustained rallies remain unlikely without stronger triggers. "For active traders, fading strength near resistance offers the best risk-reward until clear momentum shifts emerge."

Bearish momentum persists as key averages and indicators align lower

ALNY is trading below its 20-day, 50-day, and 200-day moving averages ($190.70, $221.23, and $276.39 respectively), underscoring sustained bearish pressure across all main timeframes. Near-term technical setup shows resistance at $167.99 and support at $161.93, with the Ichimoku Kijun line at $194.07 confirming resistance from trend levels. Momentum readings are weak: MACD and Average Directional Index (ADX) remain bearish, while the Relative Strength Index (RSI) is in the oversold zone, signaling possible selling exhaustion. Stochastic RSI and Commodity Channel Index (CCI) are neutral. Intraday, Bull/Bear Power is negative, and the Awesome Oscillator is neutral. The price gained $8.47 or 5.4% today, with an upside gap at the open and volatility at 5.64%. Although intraday action pushed toward session highs, overall momentum signals remain weak.

Earlier, analysts noted that Alnylam Pharmaceuticals was facing sustained bearish momentum despite strong earnings and pipeline updates, as persistent selling drove the stock below major technical supports. The current setup reinforces downside risk, with traders advised to monitor for a break below $158.97 as confirmation of continued weakness.

Source of Data: ALNY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.